102.20
+0.20%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Orion Oyj
Its shares trade on Nasdaq Helsinki under the ticker ORNBV.HE. It has been listed since 3 July 2006. In the fiscal year to 31 December 2025, it reported revenue of €1.89bn and net income of €500.3m. At that date it held total assets of €2.01bn and shareholders' equity of €1.28bn.
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2006-07-03. The firm is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Jul 2006
- Employees
- 3,324
- Website
- orion.fi ↗
Leadership
Pay as last reported
- Mr. Veli - Matti MattilaIndependent Chairman for the Board€121,600
- Dr. Liisa HurmePresident, Chief Executive Officer, Member of the Executive Management Board€2.3m
- Prof. Hilpi RautelinIndependent Vice Chairman of the Board€83,566
- Mr. Rene LindellChief Financial Officer, Member of the Executive Management Board
- Ms. Julia MachareySenior Vice President, People and Culture, Member of the Executive Management Board
- Ms. Satu AhomaekiSenior Vice President, Generics and Consumer Health, Member of the Executive Management Board
- Mr. Juhani KankaanpaeaeSenior Vice President, Global Operations, Fermion, Member of the Executive Management Board
- Mr. Niclas LindstedtSenior Vice President, Animal Health, Member of the Executive Management Board
- Mr. Hao PanSenior Vice President, Branded Products, Member of the Executive Management Board
- Dr. Outi VaaralaSenior Vice President, Research and Development and Innovative Medicines, Member of the Executive Management Board
- Mr. Jani KorhonenEmployee Representative on the Executive Management Board
- Mr. Kari AhoIndependent Director€63,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 88
- Social
- 99
- Governance
- 67
- Direct emissions (scope 1)
- 5,511 t
- Energy emissions (scope 2)
- 11,726 t
- Value chain emissions (scope 3)
- 417,464 t
- Women in the workforce
- 57.1%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Orion Oyj has several strengths that contribute to its market position and success. Firstly, the company has a strong brand reputation and a long history in the pharmaceutical industry. This enhances customer trust and loyalty. Additionally, Orion Oyj has a diverse product portfolio, offering a wide range of pharmaceuticals and specialty drugs, which allows the company to cater to various market segments. Furthermore, the company has a robust research and development (R&D) department, enabling innovation and the development of new and improved drugs. This helps Orion Oyj maintain a competitive edge in the market.
Weaknesses
- Despite its strengths, Orion Oyj also has weaknesses that may impact its performance. One weakness is its geographical concentration. The company's operations are primarily focused in Europe, with limited presence in other regions. This reliance on a single market exposes Orion Oyj to risks associated with regional economic downturns or changes in regulations. Moreover, the company's heavy reliance on a few key products leaves it vulnerable to market fluctuations and patent expirations. The lack of diversification in its product offerings poses a potential weakness for Orion Oyj.
Opportunities
- Several opportunities exist for Orion Oyj to capitalize on. One important opportunity is the growing demand for specialty and personalized medicine. By investing in the development of drugs tailored to specific patient needs, Orion Oyj can tap into this emerging market and gain a competitive advantage. Additionally, the increasing global aging population presents an opportunity for the company to expand its offerings in geriatric care and related pharmaceuticals. Furthermore, strategic partnerships and collaborations with other pharmaceutical companies can help Orion Oyj access new markets and enhance its distribution network.
Threats
- Orion Oyj faces various threats that could impact its operations. Firstly, intense competition within the pharmaceutical industry poses a significant threat. Other major players may introduce competing products, leading to market share erosion. Moreover, regulatory changes and stricter drug approval processes can create obstacles and delays in product development and commercialization. The ongoing globalization of the pharmaceutical industry also exposes Orion Oyj to geopolitical risks, trade barriers, and currency fluctuations. Lastly, the emergence of generic drugs, along with patent expirations, poses a threat to the company's market share and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.